K
Kenneth P. Karey
Researcher at Genzyme
Publications - 9
Citations - 768
Kenneth P. Karey is an academic researcher from Genzyme. The author has contributed to research in topics: Acid sphingomyelinase & Niemann–Pick disease. The author has an hindex of 8, co-authored 9 publications receiving 708 citations.
Papers
More filters
Journal ArticleDOI
Integrated continuous production of recombinant therapeutic proteins
Veena Warikoo,Rahul Godawat,Kevin Brower,Sujit Jain,Daniel Cummings,Elizabeth Simons,Johnson Timothy,Jason Walther,Marcella Yu,Benjamin Wright,Jean McLarty,Kenneth P. Karey,Chris Hwang,Weichang Zhou,Frank Riske,Konstantin Konstantinov +15 more
TL;DR: The first successful demonstration of the integration of a perfusion bioreactor and a four‐column periodic counter‐current chromatography system for the continuous capture of candidate protein therapeutics is reported, demonstrating the potential of integrated continuous bioprocessing as a universal platform for the manufacture of various kinds of therapeutic proteins.
Journal ArticleDOI
Activation of human acid sphingomyelinase through modification or deletion of C-terminal cysteine.
Huawei Qiu,Tim Edmunds,Jennifer Baker-Malcolm,Kenneth P. Karey,Scott Estes,Cordula Schwarz,Heather Hughes,Scott M. Van Patten +7 more
TL;DR: Results indicate that purified rhASM can be activated in vitro by loss of the free thiol on the C-terminal cysteine via chemical modification, dimerization, or deletion of this amino acid residue.
Journal ArticleDOI
Accelerated Clone Selection for Recombinant CHO Cells Using a FACS-Based High-Throughput Screen
Christine Demaria,Victor R. Cairns,Cordula Schwarz,Jin Zhang,Megan Guerin,Erin Zuena,Scott Estes,Kenneth P. Karey +7 more
TL;DR: This method provides an effective process for generating recombinant cell lines producing high levels of therapeutic proteins, with the benefits of rapid and accurate 96‐well plate clone screening and elimination of unstable clones at an earlier stage in the development process.
Journal ArticleDOI
Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann–Pick A disease
James Dodge,Jennifer Clarke,Christopher M. Treleaven,Tatyana V. Taksir,Denise Griffiths,Wendy Yang,Jonathan A. Fidler,Marco A. Passini,Kenneth P. Karey,Edward H. Schuchman,Seng H. Cheng,Lamya S. Shihabuddin +11 more
TL;DR: The effectiveness of intracerebroventricular delivery of recombinant human ASM into ASMKO mice showed that ICV delivery of the enzyme led to widespread distribution of the hydrolase throughout the CNS and a significant reduction in lysosomal accumulation of sphingomyelin was observed throughout the brain and also within the spinal cord and viscera.
Journal ArticleDOI
Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics.
James M. Murray,Anne Marie Thompson,Allison Vitsky,Michael L. Hawes,Wei-Lien Chuang,Joshua Pacheco,Stephen Wilson,John M. McPherson,Beth L. Thurberg,Kenneth P. Karey,Laura Andrews +10 more
TL;DR: The results suggest that the nonclinical safety assessment of novel therapeutics should include the use of specific animal models of disease whenever feasible, and the observed toxicity involves the rapid breakdown of large amounts of sphingomyelin into ceramide and/or other toxic downstream metabolites, which are known signaling molecules with cardiovascular and pro-inflammatory effects.